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8-Br-cGMP	 8-Bromo-cyclic	guanylate		
	 monophosphate
BrdU	 5-Bromo-2-deoxyuridine
ETU	 2-ethyl-thiopseudourea
ODQ	 1H-[1,2,4]-oxadiazolo-[4,3-	
	 a]-quinoxalin-1-one
D-NAME	 D-nitro-arginine-methyl		
	 ester
L-NAME	 L-nitro-arginine-methyl	ester
SNAP	 S-nitroso-N-acetyl-penicilla-	
	 mine
sGC	 soluble	guanylate	cyclase
XNOS1	 Xenopus	nitric	oxide	synthase	1
dnXNOS1	 dominant	negative	XNOS1
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AbStRAct
The establishment of a vertebrate body plan during embryogenesis is achieved 
through precise coordination of cell proliferation and morphogenetic cell movements. 
Here we show that nitric oxide (NO) suppresses cell division and facilitates cell 
movements during early development of Xenopus, such that inhibition of NO synthase 
(NOS) increases proliferation in the neuroectoderm and suppresses convergent extension 
in the axial mesoderm and neuroectoderm. NO controls cell division and cell movement 
through two separate signaling pathways. Both rely on RhoA-ROCK signaling but can be 
distinguished by the involvement of either guanylate cyclase or the planar cell polarity 
regulator Dishevelled. Through the cGMP-dependent pathway, NO suppresses cell 
division by negatively regulating RhoA and controlling the nuclear distribution of ROCK 
and p21WAF1. Through the cGMP-independent pathway, NO facilitates cell movement 
by regulating the intracellular distribution and level of Dishevelled and the activity of 
RhoA, thereby controlling the activity of ROCK and regulating actin cytoskeleton remod-
eling and cell polarization. Concurrent control by NO helps ensure that the crucial 
processes of cell proliferation and morphogenetic movements are coordinated during 
early development. 
iNtRoductioN
During	 the	 early	 steps	 of	 development,	 two	 major	 morphogenetic	 processes,	 cell	
division	and	cell	movement,	are	tightly	integrated.	Active	cell	duplication	is	required	to	
generate	a	sufficient	number	of	cells;	it	must	be	coordinated	with	precise	morphogenetic	
cell	 movements	 during	 gastrulation	 and	 organogenesis	 to	 build	 a	 correctly	 structured	
organ	or	a	tissue	and	discoordination	of	these	processes	may	lead	to	morphogenetic	aberra-
tions	and	congenital	malformations	(e.g.,	neural	tube	defects).1-6	However,	the	alterations	
of	 cell	 shape	 and	 cytoskeleton	 rearrangements	 required	 for	 the	 complex	 choreography	
of	moving	cell	sheets	in	the	embryo	may	be	incompatible	with	cell	division;	conversely,	
mitoses	may	disrupt	the	polarized	cytoskeletal	structures	necessary	for	the	directed	migra-
tion	of	cells	during	embryogenesis.	Indeed,	the	process	of	cell	division	disrupts	the	planar	
polarity	of	neuroepithelial	cells	which	is	required	for	the	correct	trajectory	of	movement	
of	these	cells	in	the	developing	neural	tube;	planar	polarity	has	to	be	reestablished	in	the	
migrating	cells	of	the	neuroepithelium	after	each	mitosis.7
The	 nature	 of	 the	 signals	 that	 coordinate	 cell	 division	 and	 cell	 movement	 during	
development	has	been	elusive.	Here	we	 show	that	NO,	a	 signaling	molecule	with	both	
antiproliferative8-15	and	pro-motility16-19	potential,	regulates	the	machineries	both	of	cell	
division	and	cell	motility	during	Xenopus	development.	Changes	in	NO	availability	affect	
the	two	processes	in	a	reciprocal	manner:	NO	suppresses	cell	division	and	facilitates	cell	
movement,	whereas	a	deficit	of	NO	increases	cell	proliferation	and	hinders	cell	movement.	
NO	 acts	 as	 a	 negative	 regulator	 of	 the	 RhoA-ROCK	 pathway:	 in	 a	 cGMP-dependent	
manner,	it	affects	cell	division	by	controlling	the	intracellular	distribution	of	ROCK	and	
p21WAF1;	 in	a	 cGMP-independent	manner	 it	 affects	 cell	movements	 through	 interac-
tions	with	 the	Disheveled	 (Dsh)	component	of	 the	planar	cell	polarity	 (PCP)	pathway,	
S-nitrosylation	of	RhoA,	control	of	ROCK	activity,	and	remodeling	of	the	actin	cytoskel-
eton.	These	results	reveal	a	molecular	mechanism	for	the	coordination	of	cell	division	with	
morphogenetic	cell	movements	during	early	vertebrate	development.
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mAtERiAlS ANd mEthodS
Recombinant constructs.	 XNOS1	 gene	 (GenBank	 assession	
number	AF053935)	 isolation	was	 described	 earlier	 in	 ref.	 12.	The	
dnXNOS1	construct	was	prepared	by	deleting	an	Xba	 fragment	of	
XNOS1	 encompassing	272	 carboxy-terminal	 amino	 acids	 covering	
the	NADPH	binding	 domain	 and	 cloning	 the	 resulting	 truncated	
cDNA	 into	 the	 pCS2	 plasmid.	The	 efficiency	 of	 XNOS1	 inhibi-
tion	by	dnXNOS1	was	evaluated	after	co-transfection	of	293T	cells	
with	 XNOS1	 and	 dnXNOS1	 DNA	 and	 assaying	 NOS	 activity	
in	 transfected	 cells	 using	 the	 arginine-citrulline	 conversion	 assay	
(as	 described	Refs.	 12,20).	NOS	 activity	 in	 embryos	 injected	with	
XNOS1	 and	 dnXNOS1	 mRNA	 was	 also	 evaluated	 in	 situ	 by	
NADPH-diaphorase	 reaction	 as	 described	 in	 ref.	 12.	 dnXNOS1,	
XNOS1-HA,	 XNOS1-GFP	 constructs	 were	 prepared	 using	 stan-
dard	 molecular	 cloning	 techniques.21	 Dsh-myc,	 Dsh-GFP,	 and	
p21WAF1-myc	 constructs	 were	 gifts	 from	Drs.	 S.	 Sokol,	 Y.	 Sasai,	
and	S.	Ohnuma,	respectively.	RNA	for	microinjections	was	prepared	
using	mMessage	mMachine	kit	(Ambion,	Austin,	TX)	according	to	
the	manufacturer’s	manual.
Embryo handling and microinjections.	Eggs	were	obtained	after	
induced	ovulation	of	 female	Xenopus laevis	by	 injections	of	human	
chorionic	 gonadotropin.	 Eggs	 were	 fertilized	 in	 vitro,	 dejellied	 in	
3%	cysteine	(pH	7.9)	and	reared	in	0.3	MMR.	Embryos	were	staged	
according	to	Nieukoop	and	Faber.22
Microinjections	 of	 embryos,	 placed	 in	 3%	 ficoll	 in	 0.3	MMR,	
was	 performed	 using	 a	Harvard	Apparatus	microinjector	 PLI-100.	
10	 nl	 of	 NOS	 inhibitors	 2-ethyl-2-thiopseudourea	 (ETU;	 10	 or	
100	 mM	 stock	 concentration);	 L-nitro-arginine-methyl	 ester	
(L-NAME;	 100	 or	 1000	mM	 stock	 concentration),	 or	 its	 inactive	
enantiomer	 D-NAME,	 S-nitroso-N-acetyl-penicillamine	 (SNAP;	
10	mM	stock	 concentration),	 and	RhoA	kinase	 (ROCK)	 inhibitor	
Y27632	 (100	mM	 stock	 concentration),	 8-Bromo-cyclic	 guanylate	
monophosphate	 (8-Br-cGMP;	 10	 mM	 stock	 concentration),	 or	
sGC	 inhibitor	 1H-[1,2,4]-oxadiazolo-[4,3-alpha]-quinoxalin-1-one	
(ODQ;	1	mM	stock	concentration)	(all	from	Calbiochem,	San	Diego,	
CA),	 were	 injected	 into	 the	 blastocoel	 of	 stage	 8	 embryos.	 In	 the	
experiments	aimed	at	perturbing	NO	signaling	in	dorsal	structures,	
1.5	ng	of	either	XNOS1	or	dnXNOS1	mRNA,	along	with	0.5	ng	of	
either	b-galactosidase	or	GFP	mRNA	(used	as	tracers)	was	injected	
into	the	two	dorsal	blastomeres	of	the	four-cell	embryo.	To	perturb	
NO	signaling	on	one	side	of	the	embryo,	mRNAs	were	injected	into	
one	 blastomere	 of	 the	 two-cell	 stage	 embryo.	 Successfully	 injected	
embryos	were	selected	for	further	analysis	by	epifluorescence	of	the	
GFP	 tracer	 under	 Nikon	 SMZ-U	 dissecting	 microscope	 or	 after	
staining	 with	 5-bromo-6-chloro-3-indolyl-b-D-galactopyranoside	
substrate	 for	b-galactosidase	 (Biotium,	Hayward,	CA)	 as	 described	
in	ref.	23.	To	access	the	changes	in	cellular	organization,	notochords	
were	dissected	from	stage	23	embryos	and	stained	by	fluorescein-la-
beled	concanavalin	A	and	Topro3	(Molecular	Probes,	Eugene,	OR).
Animal	caps	were	prepared	at	the	late	blastula	stage	and	cultured	
in	0.6	MMR.23	L-NAME	or	D-NAME	was	added	at	concentration	
of	5	mM,	SNAP	at	200	mM,	Y27632,	8-Br-cGMP	at	100	mM,	and	
ODQ	at	10	mM.	For	the	animal	cap	elongation	assay	the	media	was	
supplemented	with	10	ng/mL	of	human	recombinant	activin	(R&D,	
Minneapolis,	MN)	or	with	activin	along	with	L-NAME,	SNAP,	or	
Y27632	at	the	concentrations	stated	above.	All	groups	were	harvested	
and	fixed	in	MEMFA23	when	untreated	sibling	embryos	reached	the	
late	neurula	stage.
Immunocytochemistry.	 For	 whole	 mount	 immunochemistry	
experiments	 animal	 caps	 were	 postfixed	 15	min	 in	Dent’s	 fixative	
(20%DMSO,	80%	Methanol),23	cut	into	small	pieces,	and	processed	
for	whole	mount	immunochemistry	according	to	the	Klymkowsky’s	
lab	protocol	 (spot.colorado.edu/~klym/Methods/wholemount.htm).	
Polyclonal	 antibody	M-19	 to	 p21WAF1	 (sk-471	 from	 Santa-Cruz	
Biotechnology,	 Santa	Cruz,	CA;	 lot	H262,	 gift	 from	D.	Helfman)	
(dilution	1:400),	polyclonal	antibody	to	Dsh	(a	gift	from	S.	Sokol)	
(dilution	 1:200),	 and	 monoclonal	 antibodies	 to	 ROCKI	 and	
ROCKII	 (Transduction	 Laboratories/BD	 Pharmingen,	 San	 Jose,	
CA)	(dilution	1:200)	were	applied	and	were	followed	by	secondary	
anti-rabbit	 or	 anti-mouse	 antibodies	 conjugated	 to	 Alexa	 488	 or	
Alexa	568	(Molecular	Probes)	(dilution	1:400).	Falloidin-Alexa	488	
was	 from	 Molecular	 Probes.	 Nuclei	 were	 stained	 with	 Topro3	 or	
SYBR-Green	 (Molecular	Probes).	 Images	were	 collected	on	 a	Zeiss	
LSM510	confocal	microscope.
In situ hybridization, marker analysis.	 Wholemount	 in	 situ	
hybridizations	 were	 carried	 out	 using	 the	 digoxygenine/alkaline	
phosphatase	 detection	 method	 (Roche	 Molecular	 Biochemicals,	
Mannheim,	 Germany)	 as	 described	 in	 ref.	 23.	 The	 constructs	
to	 prepare	 hybridization	 probes	 were	 gifts	 from	 Drs.	 P.	 Krieg,	 Y.	
Sasai,	 and	 S.	 Sokol.	 For	 5-bromo-2-deoxyuridine	 (BrdU)	 labeling,	
embryos	 at	 late	 neurula	 stage	were	 injected	with	BrdU	 at	 concen-
tration	 1	 mg/ml,	 fixed	 after	 two	 hours	 in	 4%	 paraformaldehyde,	
treated	with	proteinase	K,	post	fixed	in	Dent’s	fixative,	and	processed	
with	 FITC-conjugated	 anti-BrdU	 antibody	 (BD	 Pharmingen)	 as	
suggested	 by	 the	manufacturer.	 Labeled	 embryos	 or	 explants	 were	
placed	 in	 FocusClear	 (Pacgen,	 Vancouver,	 Canada)	 to	make	 them	
transparent	and	were	 imaged	on	confocal	microscope.	Stacks	of	20	
mm	optical	sections	were	collected.	The	assessment	of	the	changes	in	
the	cell	number	and	statistical	analysis	were	performed	as	described	
previously	in	ref.	12.
Rho‑Rhotekin pulldown assay, immunoprecipitation and 
Western blots.	 RhoA	 activation	 assays	 were	 performed	 essentially	
as	 described	 in	 ref.	 24.	 Embryos	 injected	 at	 blastula	 stage	 8	 with	
PBS,	L-NAME,	D-NAME	or	SNAP	were	harvested	at	late	neurula	
stage	 and	 protein	 extracts	 from	 20	 embryos	 were	 incubated	 with	
Rhotekin-RBD	 Protein	 GST	 beads	 (Cytoskeleton,	 Denver,	 CO).	
Proteins	 bound	 to	 Rhotekin	 beads	 were	 resolved	 by	 SDS-PAGE	
and	 blotted	 onto	 PVDF	 membrane	 (Millipore,	 Bedford,	 MA);	
signals	 were	 visualized	 using	 antibody	 against	 RhoA	 (Santa	 Cruz	
Biotechnology)	and	chemiluminescence	Superfemtomole	kit	(Pierce,	
Rockford,	 IL).	 Immunoprecipitations	 were	 performed	 using	 stan-
dard	techniques21	and	proteins	were	analyzed	using	SDS-PAGE	and	
Western	blotting	as	above.
Biotin switch assay.	Biotin	switch	assay	to	detect	S-nitrosylation	
was	performed	essentially	as	described	in	ref.	25.	We	used	the	mouse	
brain	 microvascular	 endothelial	 cell	 line	 bend.3	 (ATCC)	 which	 is	
known	 to	 produce	 higher	 amounts	 of	 NO,	 as	 a	 model	 system	 to	
express	RhoA	gene	(gift	from	L.	van	Aelst,	CSHL).	bend.3	cells	were	
transfected	with	 a	 construct	 coding	 for	 RhoA	 tagged	with	 the	T7	
epitope	and	harvested	after	36–48	hrs.	Typically,	500	mg	of	cell	lysates	
were	used.	First,	the	free	thiols	were	blocked	with	methylmethaneth-
iosulfonate	(MMTS)	and	the	nitrosylated	thiols	were	oxidized	using	
ascorbate	 and	 tagged	 simultaneously	 with	 Biotin-HPDP.	 Finally,	
biotinylated	proteins	were	purified	using	NeutrAvidin-agarose	beads	
(Pierce,	Rockford,	IL)	and	analyzed	using	Western	blotting	and	anti-
bodies	to	T7	epitope.
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RESultS
XNOS1 regulates embryonic development of Xenopus.	XNOS1	
is	the	major	form	of	NOS	found	in	the	developing	brain	of	Xenopus	
tadpoles.12	 We	 examined	 the	 expression	 of	 XNOS1	 during	 early	
Xenopus	 development	using	 in	 situ	hybridization	 (Figs.	 1Aa-e)	 and	
NADPH	 diaphorase	 staining,	 an	 indicator	 of	 NOS	 activity	 (Figs.	
1Af-j).	Both	approaches	revealed	similar	distribution	patterns,	indi-
cating	 that	XNOS1	accounts	 for	most	of	 the	NOS	activity	during	
early	 development.	 XNOS1	 is	 detected	 as	 maternal	 RNA	 and	
protein	 in	 the	animal	hemisphere	of	 the	oocyte	and,	after	 fertiliza-
tion,	through	the	blastula	stages	of	the	embryo	(Fig.	1Aa	and	Af ).	At	
the	beginning	of	gastrulation	XNOS1	is	expressed	in	the	ectoderm	
and	 marginal	 zone	 and	 also	 in	 cells	 of	 the	 involuting	 mesoderm	
(Fig.	1Ab	and	Ag).	In	the	neurula,	XNOS1	is	expressed	in	the	dorsal	
and	lateral	mesoderm	and	in	cells	lining	the	archen-
teron	(Fig.	1Ac	and	Ah);	XNOS1	expression	in	the	
ectoderm	at	this	stage	is	limited	to	the	lateral	edges	
of	 the	 neural	 tube,	 the	 anterior	 neural	 ridge,	 pros-
encephalon,	 and	 the	 eye	 anlage	 (Fig.	 1Ad	 and	Ai).	
Later,	 in	 the	 tadpole,	 XNOS1	 is	 expressed	 in	 the	
notochord,	 the	 eye,	 and	 the	 developing	 nervous	
system	(Fig.	1Ae	and	Aj;	see	also	ref.	12).
To	 experimentally	 increase	 NO	 production,	 we	
injected	XNOS1	mRNA	into	one	or	two	blastomeres	
of	the	two-cell	embryo	or	into	two	dorsal	blastomeres	
of	the	four-cell	embryo.	To	decrease	NO	production,	
we	 similarly	 injected	 mRNA	 corresponding	 to	 a	
dominant	negative	version	of	XNOS1	(dnXNOS1,	a	
truncated	variant	of	XNOS1	lacking	the	carboxy-ter-
minal	NADPH	domain;	note	that	both	XNOS1	and	
dnXNOS1	retain	the	PDZ	domain)	(Fig.	1B).	NOS	
enzymes	require	homodimerization	to	be	active	and	
truncated	NOS	 polypeptides	 can	 suppress	 produc-
tion	of	NO	by	 forming	 inactive	heterodimers	with	
the	endogenous	full	length	NOS	polypeptide.20,26,27	
We	used	NADPH	staining	of	embryos	to	assess	the	
efficiency	 of	 modulating	 the	 NOS	 activity.	 When	
XNOS1	 mRNA	 was	 injected,	 NOS	 activity,	 as	
judged	by	NADPH	diaphorase	staining,	was	strongly	
increased	at	least	until	stage	43	(Fig.	1C).	Conversely,	
injection	of	the	mRNA	coding	for	dnXNOS1	inhib-
ited	 the	 activity	 of	 endogenous	 NOS	 (Fig.	 1C).	
This	 confirms	 that	mRNA	 from	 recombinant	 vari-
ants	 of	XNOS1	 can	be	used	 to	 effectively	 up-	 and	
down-regulate	NOS	activity	in	embryos.	In	parallel,	
we	 manipulated	 NO	 levels	 by	 injecting	 either	 an	
NO	donor	S-nitroso-N-acetyl-penicillamine	(SNAP)	
or	 NOS	 inhibitors	 L-nitro-arginine-methyl	 ester	
(L-NAME)	 and	 2-ethyl-thiopseudourea	 (ETU)	
into	 the	 blastocoel,	 using	 the	 inactive	 enantiomer	
D-NAME	or	saline	as	controls.
Injections	of	XNOS1	mRNA	or	NO	donor	did	
not	 change	 the	 course	 of	 embryo	 development.	 In	
contrast,	 injection	 of	 the	 recombinant	NOS	 inhib-
itor	 dnXNOS1	mRNA	 into	 the	 dorsal	 blastomeres	
had	a	distinct	effect	on	the	embryo	morphogenesis.	
By	 the	 end	of	 gastrulation	 (stage	12),	NOS	 inhibi-
tion	 resulted	 in	 delayed	 (by	 2–3	 hours)	 or	 incomplete	 blastopore	
closure	(81%,	n	=	210;	Fig.	2A	and	B),	and,	in	severe	cases	(~10%),	
resulted	in	failure	to	complete	gastrulation.
By	the	neurula	stage	19,	inhibition	of	XNOS1	resulted	in	a	delay	
in	neural	tube	closure	and	a	wider	(and	in	severe	cases,	open),	neural	
tube	(Fig.	2Ad	and	Ae).	Later,	by	the	early	tailbud	stage	(stage	23),	
65%	(n	=	160)	of	the	embryos	displayed	several	 types	of	defects:	a	
shortened	anteroposterior	axis;	dorsal	flexure;	and	delayed	fusion	of	
the	neural	tube	(Fig.	2Ag	and	Ah).	The	distortion	of	the	streamlined	
shape	 of	 the	 embryos	 injected	 with	 dnXNOS1	 mRNA	 was	 also	
apparent	 at	 later	 stages	of	development	 (stage	28,	Fig.	2Aj	 and	Ak	
and	stage	43,	Fig.	2Am	and	An).	Such	changes	are	characteristic	of	
defects	 in	 the	PCP	pathway	which	controls	cell	movements	during	
convergent	 extension.2,4,28	Specifically,	 the	 changes	 induced	by	 the	
NOS	 inhibitor	 resembled	 defects	 in	 both	 mesodermal	 convergent	
Figure 1. XNOS1 expression and activity. (A) XNOS1 is expressed during early Xenopus 
development. XNOS1 expression during early development detected by in situ hybridization 
(upper panel, a–e) and NADPH-diaphorase activity (lower panel, f–j): unfertilized oocytes 
(a and f; arrows point to the animal pole), beginning of gastrulation (b and g; arrow indicates 
dorsal lip), late neurula (c, d, h and i), and tadpole (e and j). Bar is 250 mm in a–d, f–i and 
500 mm in e and j. (B) Structure of XNOS1 and dnXNOS1. XNOS1 is 1419 aa long and has 
all of the conserved regions of mammalian nNOS. dnXNOS1 is 1147 aa long and lacks the 
critical NADPH-binding domain essential for the NO synthesis. (C) Modulating NOS activity 
by XNOS1 and dnXNOS1. 2 blastomeres of the 2-cell embryos were injected with XNOS1, 
b-galactosidase, or dnXNOS1 mRNA. At stage 43 brains were dissected and stained for 
NADPH-diaphorase activity. Injection of XNOS1 mRNA increased staining (left) compared 
to the injection of b-galactosidase (center); injection of dnXNOS1 strongly decreased the 
staining (right).
www.landesbioscience.com	 Cell	Cycle	 3135
NO	Coordinates	Division	and	Movement	During	Development
extension	 (short,	 stunt	 embryos)	 and	 neural	 convergent	 extension	
(dorsal	flexure	and	delayed	closure	of	the	neural	tube).
To	further	link	the	action	of	the	recombinant	NOS	inhibitor	with	
a	specific	morphogenetic	defect,	we	traced	the	site	of	expression	of	
the	injected	dnXNOS1	mRNA	by	co-injecting	it	with	GFP	mRNA	
into	the	two	dorsal	blastomeres	of	the	eight-cell	embryo	and	analyzed	
the	tadpole.	This	showed	that	the	shortened	axis	phenotype	was	asso-
ciated	with	the	presence	of	the	GFP	tracer	(and	thus,	dnXNOS1)	in	
the	notochord	(Fig.	2Ba,b,d	and	e),	consistent	with	targeting	of	the	
mRNAs	to	the	dorsal	vegetal	blastomeres	and	defects	in	mesodermal	
convergent	extension;	in	turn,	dorsal	flexure	was	associated	with	the	
appearance	of	 the	GFP	 tracer	 in	 the	neural	 tube	 (Fig.	2Bc	 and	 f ),	
consistent	with	 targeting	 of	 the	mRNA	 to	 the	 dorsal	 animal	 blas-
tomeres	and	defects	in	neural	convergent	extension.	Together,	these	
experiments	 suggest	 that	NO	is	 involved	 in	controlling	morphoge-
netic	cell	movements,	potentially	through	interactions	with	the	PCP	
pathway.
When	dnXNOS1	was	injected	into	the	blastomeres	of	the	two-cell	
embryo,	 the	embryos	underwent	apparently	normal	axis	 extension.	
However,	when	we	examined	the	embryos	during	organogenesis,	we	
found	that	inhibition	of	NOS	resulted	in	enlarged	organ	size	in	45%	
(n	=	95)	of	the	embryos.	For	example,	injections	of	dnXNOS1	into	
one	of	the	two	blastomeres	of	a	two-cell	embryo	resulted	in	enlarged	
head,	brain,	and	eye	on	the	injected,	as	compared	to	the	contralateral,	
side	(Fig.	2Bg).
Injection	 of	 chemical	NOS	 inhibitors	 L-NAME	and	ETU	 into	
the	blastocoel	 resulted	 in	 the	 same	 spectrum	of	phenotypes	as	 that	
for	the	recombinant	inhibitor	(Fig.	2Ac,f,i,l	and	o).	The	effect	of	the	
inhibitors	was	concentration-dependent	 such	 that	at	 lower	concen-
trations	(1	mM	of	L-NAME	and	100	mm	of	ETU)	the	predominant	
defect	was	an	enlargement	of	the	head,	brain,	and	eye,	while	embryos	
with	shortened	axis	and	dorsal	flexure	were	rare.	At	higher	concen-
trations	(10	mM	of	L-NAME	or	1	mM	of	ETU)	the	proportion	of	
embryos	with	 defects	 in	morphogenetic	 cell	movement	 (shortened	
axis	 and	 dorsal	 flexure)	 increased	 to	 80%	 (injection	 of	 the	 inac-
tive	 enantiomer	 D-NAME	 did	 not	 affect	 the	 development	 of	 the	
embryos).	 Thus,	 both	 types	 of	 inhibitors	 (recombinant	 inhibitor	
dnXNOS1	and	 chemical	 inhibitors	L-NAME	or	ETU)	 resulted	 in	
consistently	 similar	 phenotypes,	 attesting	 to	 the	 specificity	 of	 their	
action.	In	contrast	to	the	action	of	the	NOS	inhibitors,	elevating	NO	
levels	by	injection	of	either	XNOS1	mRNA	(Fig.	2Bh)	or	NO	donor	
SNAP	(not	shown)	resulted	in	a	smaller	head,	brain,	and	eye	(46%,	n	
=	55	for	XNOS1	and	51%,	n	=	90	for	SNAP);	however,	neither	the	
course	of	gastrulation	nor	axis	elongation	were	affected.
Together,	 the	 character	 of	 the	 defects	 induced	 by	 inhibition	 of	
NOS	 activity	 suggest	 that	 NO	 is	 involved	 in	 controlling	 several	
Figure 2. Inhibition of XNOS1 distorts morphogenesis and increases organ 
size. (A) Dorsal injections of recombinant inhibitor dnXNOS1 (b, e, h, k and 
n) or blastocoel injections of L-NAME (c, f, i, l and o) induce morphogenetic 
defects: delayed blastopore closure at the gastrula stage (b and c), a wider 
and incompletely closed neural tube at neurula stage (e and f), a shortened 
anterioposterior axis and defects in neural tube closure at the tailbud stage 
(h and i), and shortened axis and dorsal flexure in the tailbud and tadpole 
(k, l, n and o); control embryos received dorsal injections of b-galactosidase 
mRNA (a, d, g, j and m). Bar is 1 mm. (B) Targeted injections of dnXNOS1 
and lineage tracing. GFP mRNA was coinjected with either b-galactosidase 
(a and d) or dnXNOS1 mRNA (b, c, e and f) into two dorsal blastomeres 
of the eight-cell embryo. GFP lineage tracing at stage 43 shows that deliv-
ery into the notochord is associated with shortening of the axis (b and e), 
whereas delivery into the nervous system is associated with dorsal flexure 
(c and f). In separate experiments, one blastomere of the two-cell embryos 
was injected with either dnXNOS1 (g) or XNOS1 mRNA (h); in both cases 
GFP mRNA was co-injected to trace the injected side (insets). Injection of 
dnXNOS1 mRNA results in a larger head and eye on the injected side, 
whereas injection of XNOS1 mRNA results in a smaller head and eye on 
the injected side.
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aspects	 of	 early	 Xenopus	 development:	 the	 enlargement	 of	 the	
tadpole	organs	suggests	that	NO	may	be	involved	in	controlling	cell	
division,	 the	 shortened	anteroposterior	 axis	 indicates	defects	 in	 the	
convergent	 extension	of	 the	mesoderm,	whereas	 dorsal	 flexure	 and	
delayed	closure	of	the	neural	tube	suggest	defects	 in	neural	conver-
gent	extension.
NO in mesodermal convergent extension.	 Orderly	 directional	
movement	of	 the	axial	mesoderm	during	convergent	extension	and	
axis	elongation	is	necessary	for	the	formation	of	the	rod-like	structure	
of	 the	 notochord.	 Inhibition	 of	NOS	 does	 not	 affect	mesodermal	
induction,	 as	 judged	 by	 the	 expression	 of	 a	 mesodermal	 marker	
Brachiury	(Bra)	(Fig.	3a	and	b).	However,	at	the	late	gastrula	stage,	
in	 the	 embryos	 injected	 with	 dnXNOS1,	 the	 layout	 of	 posterior	
medosderm,	marked	 by	 the	 Bra	 expression,	 showed	 defects	 in	 cell	
movements	 as	mesodermal	 cells	 failed	 to	 converge	 and	 extend	 the	
midline,	leaving	the	blastopore	wide	open	(Fig.	3b).
To	 further	 examine	 whether	 a	 deficit	 of	 NO	 impairs	 morpho-
genetic	 cell	 movements	 in	 the	 mesoderm	 during	 axis	 elongation	
we	 compared	 the	notochords	 of	 embryos	 injected	with	dnXNOS1	
mRNA	 or	 control	 b-galactosidase	 mRNA.	 dnXNOS1-injected	
embryos	were	shorter	and	showed	distinct	dorsal	flexure	(Fig.	3c	and	
d)	and,	as	axis	continued	to	extend,	the	notochord	(revealed	by	Shh	
staining)	 remained	 shorter	 and	 thicker	 (Fig.	 3e	 and	 f ).	Analysis	 of	
dissected	 notochords	 revealed	 significant	 distortions	 of	 the	 normal	
cellular	order	in	the	notochords	of	the	animals	that	received	the	NOS	
inhibitor	(Fig.	3g	and	h),	indicative	of	defects	in	mesodermal	conver-
gent	extension.	To	examine	whether	inhibitor-induced	changes	in	the	
mesoderm	are	due	to	the	defects	in	cell	movement	or	to	the	excessive	
number	 of	 cells	 that	 could,	 potentially,	 distort	 the	movement,	 we	
analyzed	cell	proliferation	in	a	BrdU-labeling	experiment.	The	frac-
tion	of	BrdU-labeled	 cells	 in	 the	 total	 cell	 number	 (mitotic	 index)	
in	 the	 notochords	 of	 dnXNOS1-injected	 embryos	 did	 not	 differ	
significantly	from	the	control	(5+/-1%	vs.	7+/-2%,	Fig.	3i	and	j)	and	
was	 very	 low	 compared	 to	 the	 other	 embryonic	 tissues	 (consistent	
with	studies	showing	cessation	of	cell	division	in	the	mesoderm	after	
involution.29	These	results	indicate	that	NO	signaling	is	not	neces-
sary	 for	 suppression	 of	 cell	 division	 in	 the	 notochord	 during	 axis	
elongation.	They	also	indicate	that	the	observed	changes	in	the	noto-
chord	structure	arise	as	a	result	of	distorted	mesodermal	convergent	
extension	rather	than	excessive	cell	division.
The	 importance	 of	 NO	 for	 cell	 movement	 was	 also	 evident	
in	 vitro,	 in	 embryonic	 explants	 (animal	 caps)	 induced	 by	 activin.	
Addition	 of	 activin	 induced	 elongation	 of	 80%	 of	 the	 control	
explants	(n	=	41),	(Fig.	3k	and	l).	Adding	NOS	inhibitor	L-NAME	
to	the	media	prevented	activin-induced	elongation	of	75%	(n	=	32)	
of	 the	 explants	 (Fig.	 3m).	 In	 contrast,	 addition	 of	 the	NO	 donor	
SNAP	allowed	animal	caps	to	elongate	in	response	to	activin	similarly	
to	 the	 control	 group	 (Fig.	3n).	Together,	 the	 results	of	our	 in	vivo	
Figure 3. Inhibition of NOS distorts morphogenetic cell movements and axis 
elongation. (a and b) Inhibition of NOS does not affect mesodermal induc-
tion but distorts convergent extension. In situ hybridization with mesodermal 
marker Brachiury (Bra) of the late gastrula stage embryos which received 
injection of b-galactosidase mRNA (a) or dnXNOS1 mRNA (b). (c and d) 
Inhibition of NOS by dnXNOS1 results in shorter axis and dorsal flexure in 
tadpole stage embryos (d) as compared to the control embryos injected with 
b-galactosidase mRNA (c). (e and f) Inhibition of NOS by dnXNOS1 results 
in a thicker and shorter notochord (f) compared with the control (e). The noto-
chord was revealed by in situ hybridization with a probe for Sonic hedgehog 
(Shh). (g and h) Notochords dissected from the stage 23 embryos injected 
dorsally at the four-cell stage with b-galactosidase (g) or dnXNOS1(h) mRNA 
were stained with concanavalin A for membranes (green) and with Topro3 
for nuclei (red). Note the defects in the cellular order and shape of the noto-
chords after NOS inhibition. Bar is 20 mm in (g–j). (i and j) BrdU labeling: 
the fraction of BrdU-labeled cells (yellow) does not change after injection of 
dnXNOS1 mRNA (j) as compared to the injection of b-galactosidase mRNA 
(i) (5+/-1% vs. 7+/-2%). (k–n) NOS inhibitor prevents, whereas NO donor 
allows, the elongation of the activin-treated animal caps isolated prior to 
gastrulation. (k) untreated control animal caps; (l) animal caps treated with 
activin; (m) animals caps treated with activin and L-NAME; (n) animal caps 
treated with activin and SNAP.
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and	 in	 vitro	 experiments	 suggest	 that	 in	 the	 axial	mesoderm,	NO	
does	 not	 affect	 cell	 division	 during	 axis	 elongation	 or	mesodermal	
induction	during	gastrulation	but	is	involved	in	regulating	morpho-
genetic	cell	movements	that	underlie	convergent	extension	and	axis	
elongation.
NO in neural convergent extension.	A	wider	neural	tube,	delay	
in	neural	tube	closure,	an	open	neural	tube	during	neurulation,	and	
dorsal	flexure	at	the	tailbud	stage,	seen	in	a	large	fraction	of	embryos	
injected	with	dnXNOS1,	indicate	that	a	deficit	of	NO	affects	neural	
convergent	 extension,	 whereas	 the	 enlarged	 organ	 size	 (including	
neural	 tissue,	 Fig.	 2Bg)	 suggests	 excessive	 cell	 division.	To	 further	
analyze	 the	 changes	 in	 morphogenesis	 induced	 by	 the	 suppressed	
production	of	NO,	we	probed	the	developing	nervous	system	of	the	
embryo	at	neurula	and	tailbud	stages	by	 in	 situ	hybridization	with	
neural	marker	N-tubulin.	Suppression	of	NOS	activity	by	injection	
of	 either	 recombinant	 or	 chemical	 NOS	 inhibitors	 shortened	 the	
neural	tube	and	enlarged	the	neural	domain	(marked	by	expression	
of	N-tubulin)	as	seen	both	at	neurula	and	tailbud	stages	(Fig.	4a–g).	
Enlarged	neural	tube	was	also	detected	using	neuronal	markers	Zic1	
and	Delta	(Fig.	4h	and	i)	(note	that	in	the	experiments	in	Fig.	4e	and	
4h	only	one	of	 the	two	blastomeres	was	 injected	with	dnXNOS1).	
Furthermore,	staining	with	N-tubulin	revealed,	in	the	injected	side,	
numerous	ectopic	N-tubulin-positive	cells	away	from	the	neural	tube	
in	the	zone	of	the	epidermis	(Fig.	4e).	In	these	experiments	(as	in	the	
experiments	of	Fig.	2),	 chemical	 (Fig.	4b,d	 and	g)	or	 recombinant	
(Fig.	4e,h	and	i)	inhibitors	of	NOS	produced	similar	results,	recon-
firming	the	specificity	of	their	action.	Thus,	expansion	of	the	zone	of	
cells	expressing	neuronal	marker	genes	highlights	the	defects	induced	
in	the	developing	nervous	system	by	the	deficit	of	NO.
We	 further	 examined	 whether	 in	 the	 developing	 nervous	
system	 NO	 is	 involved	 in	 controlling	 cell	 proliferation	 (perhaps	
reflecting	its	ability	to	suppress	cell	division	in	several	developmental	
contexts8-10,13,15,30).	Incorporation	of	BrdU,	tested	at	stage	23,	was	
higher	and	occurred	in	a	wider	zone	of	the	nervous	system	in	embryos	
injected	with	inhibitor	of	NOS	that	in	control	embryos.	(Fig.	4f	and	g).	
This	 suggests	 that	 the	 increased	 proliferation	 induced	 by	 NOS	
inhibition	was	 likely	 to	 contribute	 to	 the	 enlarged	 neural	 tube	 (as	
revealed	 by	 N-tubulin	 expression).	 Importantly,	 however,	 when	
DNA	synthesis	was	suppressed	by	aphidicolin	and	hydroxyurea31	to	
deduct	the	contribution	of	increased	cell	proliferation	to	the	observed	
phenotype	(Fig.	4j),	the	neural	tube	remained	wider	and	shorter	in	
embryos	injected	with	NOS	inhibitors	as	compared	to	the	controls.	
This	 shows	 that	defects	 in	neural	convergent	extension	 induced	by	
inhibition	of	NOS	activity	are	not	merely	consequences	of	increased	
cell	proliferation	and	indicates	an	independent	involvement	of	NO	
in	cell	movement.
Together,	 the	 observations	 of	 the	 wide	 and	 shorter	 neural	 tube	
and	 delayed	 fusion	 of	 the	 neural	 tube	 at	 neurula	 stage	 and	 of	
the	 dorsal	 flexure	 observed	 at	 tailbud	 stage	 indicate	 that	 NO	 is	
important	 for	neural	 convergent	 extension.	Furthermore,	 increased	
BrdU	 incorporation	 when	NOS	 is	 inhibited	 indicates	 that	NO	 is	
Figure 4. Inhibition of XNOS1 distorts neural convergent extension and 
induces excessive cell proliferation in the ectoderm. (a–d) In situ hybridiza-
tion for N-tubulin at neurula (a, control embryo; b, embryo injected with 
NOS inhibitor) and tailbud (c, control embryo; d, embryo injected with NOS 
inhibitor) stages shows that inhibition of NOS results in a wider, shorter, 
and incompletely fused neural tube. (e–g) In situ hybridization at neurula 
stage with N-tubulin (e–g), Zic1 (h), and Delta (i) of embryos injected with 
dnXNOS1 mRNA and b-galactosidase (used as a tracer) mRNA (e, g, i) or 
with D-NAME (f) and L-NAME (g). In (e and h), embryos were injected into 
one blastomere of the two-cell embryo (arrow marks injected side, revealed 
by expression of b-galactosidase); note the widened neural tube (e and h) 
and ectopic N-tubulin-positive cells on the injected side of the embryo (e). In 
(i), embryos were injected into two dorsal blastomeres of the 4-cell embryo; 
note the enlarged anterior nervous system and a broader neural tube (control 
embryo on the left was injected with b-galactosidase mRNA only). In (f and 
g), embryos were injected at blastula stage with D-NAME (f) or L-NAME 
(g), labeled at stage 23 with BrdU, and analyzed for N-tubulin expression 
and BrdU incorporation (green, insets); note the wide neural tube and 
increased number of BrdU-labeled cells in embryos injected with L-NAME (g). 
(j) embryos injected with dnXNOS1 mRNA and raised in conditions blocking 
cell proliferation (media containing DNA synthesis inhibitors aphidicolin and 
hydroxyurea) (right) still display a wider neural tube than control embryos 
injected with b-galactosidase mRNA and grown under the same conditions 
(left), indicating that defects in cell movements caused by NOS inhibitors are 
independent of their effect on proliferation.
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also	important	for	restricting	cell	division	in	the	developing	nervous	
system	during	axis	elongation.	This	dual	action	of	NO	in	the	neuro-
ectoderm	 contrasts	with	 its	 action	 in	 the	 axial	mesoderm	where	 it	
is	important	for	the	regulation	of	convergent	extension	but	not	cell	
division.
cGMP‑dependent pathway controls antiproliferative action of 
NO.	We	 next	 examined	 whether	 soluble	 guanylate	 cyclase	 (sGC),	
a	major	effector	of	 the	action	of	NO,	 is	 involved	 in	NO-mediated	
control	 of	 cell	 movement	 and	 cell	 proliferation	 during	 embryonic	
development	 in	 Xenopus.	 We	 used	 8-Bromo-cyclic	 guanylate	
monophosphate	 (8-Br-cGMP)	 and	 sGC	 inhibitor	 1H-[1,2,4]-oxad
iazolo-[4,3-alpha]-quinoxalin-1-one	(ODQ),	to	activate	or	suppress	
cGMP	signaling,	respectively.	When	8-Br-cGMP	was	injected	at	the	
blastula	 stage,	 the	 embryos,	 while	 maintaining	 apparently	 normal	
body	 shape,	 entered	 neurulation	 with	 a	 slight	 delay	 and	 appeared	
smaller	during	axis	elongation	(stage	23;	Fig.	5Aa,b,f	and	g).	BrdU	
labeling	 of	 stage	 23	 embryos	 indicated	 that	 an	 increase	 of	 cGMP	
levels	 inhibits	 cell	proliferation.	 (Fig.	5Ak	and	 l).	 In	contrast,	 sGC	
inhibitor	 ODQ	 increased	 cell	 proliferation	 in	 neural	 tube,	 acting	
similarly	 to	NOS	 inhibitor	L-NAME	(Fig.	5Am	and	n).	However,	
unlike	 L-NAME,	ODQ	did	 not	 induce	 defects	 in	 axis	 elongation	
and	morphogenesis	(Fig.	5Ac	and	h).	These	experiments	suggest	that	
Figure 5. cGMP mediates the antiproliferative action of NO during early development. (A) Embryos were injected at blastula stage with saline, 8-Br-cGMP, 
ODQ, L-NAME, or L-NAME with 8-Br-cGMP; types of treatment are indicated. Part of the animals in each group were examined for phenotypic changes at 
stage 19 (a–e) and for the changes in phenotype and cell proliferation at stage 23 (f–o) (remaining animals were analyzed at stage 43, see Fig. 5B). For 
the analysis of cell proliferation in the developing neural tube, embryos were labeled with BrdU at stage 23 for 2 hr and neural tubes were dissected and 
analyzed for cell proliferation by staining for BrdU-positive cells (green) (k-o) and for the total number of cells by staining with Topro3. (m) shows mitotic 
indices in the neural tube for each treatment calculated as a ratio of BrdU-positive to the total (Topro3-stained) cells: BrdU incorporation is increased in the 
neural tube of animals treated with L-NAME and ODQ and decreased in animals treated with 8-Br-cGMP or with 8-Br-cGMP in combination with L-NAME. 
For both (A and B), bar is 1 mm for the images of whole embryos and 200 mm for the images of BrdU-labeling experiments. (B) Embryos from the same 
experimental groups as in (A) were examined at stage 43; types of treatments correspond to those in (A). The animals were analyzed for morphology (a–e) 
and then examined by sectioning and staining the nuclei with SYBR Green (f–j). In 5Bf–j, insets on the left of the image show high magnification view of the 
retina of the eye, insets on the right show high magnification view of the tectum area of the brain; note the reduced cell number in the retina and the brain 
of the 8-Br-cGMP-treated embryos and the increased cell number and cell density in these areas in the ODQ-treated animals.
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cGMP-dependent	 signaling	may	underlie	 the	 effect	of	NO	on	 cell	
proliferation,	 but	 not	 on	 cell	 movement.	 Indeed,	 when	 we	 exam-
ined	whether	 8-Br-cGMP	can	 rescue	 the	 defects	 induced	by	NOS	
inhibitor,	we	found	that,	although	the	L-NAME-induced	increase	in	
cell	proliferation	 in	 the	neural	 tube	was	 suppressed	by	8-Br-cGMP	
(Fig.	 5An	 and	 o),	 the	 defects	 in	 cell	movements	 seen	 as	 a	 thicker	
neural	 tube	 and	 a	 shorter	 axis,	 were	 still	 apparent	 (Fig.	 5Ad,e,i	
and	j).
We	next	 examined	 the	 animals	 at	 the	 tadpole	 stage	43.	Among	
8-Br-cGMP	 injected	animals,	90%	(n	=	72)	 looked	 smaller	overall	
(Fig.	5Ba	and	b)	and,	after	sectioning,	showed	reduced	cell	number	
in	 the	 brain	 and	 the	 eye	 (nuclear	 staining	 of	 the	 sections	 with	
SYBR-Green;	Fig.	5Bf	and	g).	In	contrast,	injection	of	ODQ	resulted	
in	 an	 increased	 size	 of	 the	 embryo	 and	 increased	 cell	 number	 and	
cell	 density	 in	 the	 brain	 and	 the	 eye	 (72%,	 n	 =	 85;	 Fig.	 5Bc	 and	
h).	This	 effect	 of	 ODQ	 resembles	 the	 action	 of	 NOS	 inhibitors;	
importantly,	however,	unlike	the	changes	induced	by	NOS	inhibitors,	
the	action	of	ODQ	was	not	accompanied	by	defects	 in	convergent	
extension	or	 axis	 elongation	at	 the	 tadpole	 stage.	As	 seen	at	 earlier	
stages,	 embryos	 co-injected	 with	 8-Br-cGMP	 and	 L-NAME	 were	
smaller	than	control	embryos	or	L-NAME-injected	embryos	but	still	
showed	defects	in	convergent	extension;	i.e.,	8-Br-cGMP	prevented	
the	increase	in	cell	number	induced	by	the	NOS	inhibitor	(and	even	
reduced	 it	compared	 to	 the	control)	but	did	not	 rescue	 the	defects	
in	convergent	extension	and	axis	elongation	induced	by	the	inhibitor	
(Fig.	5Bd,e,i	and	j).
Together,	these	results	indicate	that	NO	acts	on	cGMP-dependent	
pathways	 to	 suppress	 cells	 proliferation	 in	 the	 developing	 nervous	
system.	 They	 also	 indicate	 that	 NO	 uses	 cGMP-independent	
pathways	 to	 exert	 its	 effects	 on	 morphogenetic	 cell	 movements.	
Furthermore,	 these	data	provide	 additional	 support	 to	 our	 conclu-
sion	that	the	effects	of	NO	on	cell	motility	are	independent	of	those	
on	cell	division	and	demonstrate	that	these	effects	can	be	uncoupled	
through	modulation	of	cGMP	production.
NO acts as a negative regulator of RhoA‑ROCK signaling.	
When	 analyzing	 the	 pattern	 of	 XNOS1	 expression	 in	 the	 dorsal	
mesoderm	during	gastrulation	and	neurulation	(Fig.	1Ac	and	h),	we	
noticed	 that	 it	 resembled	 that	 of	RhoA,32	whose	 activity	 is	 critical	
for	 morphogenetic	 cell	 movement	 in	 Xenopus.32-34	 The	 effect	 of	
RhoA	on	cell	migration	and	cell	proliferation	is	regulated	by	NO	in	
several	 contexts;17,35-38	 furthermore,	 phosphorylation	 of	 RhoA	 by	
cGMP-dependent	 protein	 kinase	 (PKG)	 inhibits	 RhoA	 activity.39	
Based	on	these	observations,	we	asked	whether	RhoA	may	mediate	
the	action	of	NO	during	Xenopus	development.
To	 investigate	whether	NO	controls	RhoA	activity,	we	analyzed	
the	active	GTP-bound	form	of	RhoA	in	early	tailbud	stage	embryos	
injected,	prior	to	gastrulation,	either	with	the	NO	donor	SNAP	or	
the	NOS	inhibitor	L-NAME	(Fig.	6A).	Exposure	to	the	NO	donor	
decreased	the	amount	of	the	GTP-bound	form	of	RhoA	as	a	fraction	
of	 total	 RhoA.	 In	 contrast,	NOS	 inhibitor	 resulted	 in	 an	 increase	
in	the	fraction	of	the	active	form.	This	 indicates	that	NO	acts	as	a	
negative	regulator	of	RhoA	activity	during	the	early	stages	of	Xenopus	
development.
Figure 6. NO regulates early development through suppression of RhoA-ROCK. 
(A) NO negatively controls RhoA activity. Embryos were injected with either 
NO donor SNAP, NOS inhibitor L-NAME, or saline, and protein extracts 
were examined for RhoA activity. Active (GTP-bound) RhoA molecules were 
pulled down after incubation with Rhotekin-beads and analyzed by Western 
blotting with anti-RhoA antibody. Upper bands show the total expression 
of RhoA in the extracts. The numbers below each lane represents the frac-
tion of the active RhoA molecules within the total RhoA molecules, with the 
levels in untreated embryos taken as 100%. (B) S-nitrosylation of RhoA. 
S-nitrosylation status was examined using the biotin switch assay after trans-
fection of RhoA-T7 constructs into bend.3 cells and probed using antibody 
to the T7 tag. (C and D) Inhibition of ROCK rescues the defects induced by 
inhibition of NOS. (C) Embryos were injected at blastula stage with saline 
(a), L-NAME (b), ROCK inhibitor Y27632 (c; inset shows microcephaly of the 
Y27632-injected embryos at the tadpole stage, injected embryo is marked 
by arrow, control embryo on the left), or L-NAME with Y27632 (d). (D) In 
situ hybridization for N-tubulin of the same experimental groups of animals. 
Embryos injected with L-NAME (Cb and Db) show defects in axis elonga-
tion and neural tube formation; also note a more intense N-tubulin staining, 
larger anterior nervous system and numerous scattered neurons off the neural 
tube. Injection with Y27632 along with L-NAME rescued the defects of the 
L-NAME-injected embryos and normalized axis extension and neural tube 
formation (Cd and Dd).
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An	 important	 mechanism	 of	 protein	 regulation	 by	 NO	 is	 via	
S-nitrosylation	 of	 cysteine	 residues.40	We	 probed	 the	 nitrosylation	
status	of	RhoA	in	NO-producing	cells	by	employing	the	biotin-switch	
method25	and	found	nitrosylated	RhoA	molecules	in	the	cell	extracts	
(Fig.	6B).	This	modification	could	not	be	detected	when	cells	were	
incubated	with	NOS	inhibitor	L-NAME,	confirming	that	RhoA	is	
nitrosylated	by	the	action	of	NOS	in	vivo.
Since	 excessive	 activity	 of	 RhoA	 may	 underlie	 the	 phenotypes	
resulting	from	inhibition	of	NOS	activity	and	since	in	many	settings	
RhoA	 action	 is	 mediated	 by	 RhoA-dependent	 kinase	 ROCK,	 we	
asked	 if	 inhibition	 of	 ROCK	 can	 compensate	 for	 increased	 RhoA	
signaling	and	rescue	the	defects	induced	by	inhibition	of	NOS.	We	
found	 that	 injection	 of	Y27632,	 a	 specific	 inhibitor	 of	ROCK,	 in	
conjunction	with	dnXNOS1	or	L-NAME	rescued	the	defects	caused	
by	 NOS	 inhibitors	 and	 restored	 the	 normal	 phenotype	 in	 70%	
(n	=	40)	of	the	affected	embryos	(analyzed	at	the	tailbud	stage,	Fig.	
6C	and	D):	it	restored	normal	axis	extension	and	neural	tube	folding,	
eliminated	 dorsal	 flexure,	 prevented	 the	 appearance	 of	 ectopic	
neurons	away	from	the	neural	tube,	and	normalized	anterior	neural	
tube	 formation.	Y27632	 alone	did	not	 elicit	 noticeable	 changes	 in	
the	developing	embryo	and	the	nervous	system	of	the	tailbud-stage	
embryo	(except	 for	 the	embryos	appearing	 slightly	 smaller	overall);	
Figure 7. NO controls cell proliferation and cellular distribution of ROCK and p21WAF1 in animal caps. (A) NO regulates cells proliferation in the animal 
caps. NO donor SNAP suppresses cell proliferation in the ectoderm of animal caps (b), whereas NOS inhibitor L-NAME induces excessive cell prolifera-
tion (c), as compared to the control (a). Red - Topro3 staining of nuclei, green - BrdU labeling of dividing cells. Bar is 20 mm in a–c. (B) NO controls the 
cellular distribution of ROCK and p21WAF1. (a–c) animal caps stained with anti-ROCK1 antibody; types of treatments are indicated. Note an increase in 
the number of cells with nuclear localization of ROCK1 after incubation with SNAP (b), and a decrease after incubation with L-NAME (c). Experiments with 
antibodies to ROCKII gave similar results (not shown). (d–h) animal caps stained with anti-p21WAF1 antibody; types of treatment are indicated. p21WAF1 
localizes primarily in the nuclei in untreated cells (d); exposure to SNAP increases (e), whereas exposure to L-NAME strongly decreases (f), the fraction of 
cells with nuclear localization of p21WAF1. Addition of Y27632 to L-NAME (h) reverses the changes induced by L-NAME and restores a predominantly 
nuclear localization of p21WAF1. Bar is 20 mm in (a–h). (C) sGC mediates the effect of NO on the cellular distribution of p21WAF1. Fertilized eggs were 
injected with trace amounts of mRNA coding for p21WAF1-myc protein fusion and animal caps derived from the embryos were treated with L-NAME, 
SNAP, ODQ, 8-Br-cGMP, and L-NAME with 8-Br-cGMP (types of treatment are indicated); distribution of p21WAF1-myc was followed by staining with 
anti-myc antibody. The changes in the cellular distribution of the myc-tagged p21WAF1-myc in response to L-NAME and SNAP are similar to those of the 
endogenous p21WAF1 (compare to Fig. 7Bd–h). ODQ, an inhibitor of sGC activity, decreases nuclear accumulation of p21WAF1-myc. Treatment with 
8-Br-cGMP stimulates nuclear accumulation of p21WAF1-myc and is able to overcome the action of the NOS inhibitor L-NAME and retain p21WAF1-myc 
in the nucleus. Bar is 20 mm in (a–f).
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later,	 at	 the	 tadpole	 stage,	 81%	 (n	 =	 70)	 of	 the	 Y27632-injected	
embryos	 developed	 microcephaly	 (Fig.	 6Cc,	 inset).	 Together,	 our	
data	 indicate	 that	 the	 RhoA-ROCK	 pathway	 mediates	 the	 action	
of	NO	upon	both	cell	proliferation	and	cell	movement	during	early	
development	of	Xenopus.
To	 gain	 insight	 into	 how	 the	 RhoA-ROCK	
pathway	may	 link	NO	 to	 cell	 cycle	 regulation,	 we	
examined	 how	 modulation	 of	 NO	 levels	 affects	
cell	 proliferation	 and	 localization	 of	 ROCK	 in	
animal	 caps	 (consisting,	 in	 the	 absence	 of	 activin,	
of	 ectodermal	 cells).	 BrdU	 labeling	 of	 animal	 caps	
isolated	 at	 blastula	 stage	 and	 cultivated	 untill	 their	
intact	sibling	reached	neurula	stage	showed	that	NO	
donor	 SNAP	 resulted	 in	 a	 decrease	 in	 cell	 prolif-
eration,	while	NOS	 inhibitor	L-NAME	resulted	 in	
excessive	 proliferation	 (Fig.	 7Aa–c),	 an	 observation	
consistent	with	the	data	obtained	on	several	animal	
models.8-10,12,14
In	 control	 animal	 caps	 ROCK	 localization	 was	
mainly	 cytoplasmic	 but	 ROCK	 was	 also	 detected	
in	 the	nucleus	 of	 a	 fraction	of	 the	 cells	 (Fig.	 7Ba).	
The	NO	donor	SNAP	increased	the	number	of	cells	
with	 nuclear	 localization	 of	 ROCK	 (Fig.	 7Bb).	 In	
contrast,	 the	 NOS	 inhibitor	 L-NAME	 drastically	
decreased	the	number	of	cells	with	nuclear	localiza-
tion	 of	ROCK	 (Fig.	 7Bc).	Thus,	 our	 data	 indicate	
that	 in	 ectodermal	 cells	NO	 regulates	 the	 distribu-
tion	of	ROCK	between	the	nucleus	and	cytoplasm.
In	 cultured	 cells,	 ROCK	 can	 be	 detected	 in	 a	
complex	 with	 the	 cyclin-dependent	 kinase	 (cdk)	
inhibitor	 p21WAF1	 and	 cytoplasmic	 sequestration	
of	 this	 complex	 prevents	 cell	 cycle	 arrest.41,42	 We	
asked	 whether	 NO,	 by	 controlling	 the	 distribu-
tion	 of	 ROCK,	may	 also	 affect	 the	 distribution	 of	
p21WAF1	 in	 animal	 cap	 cells.	We	 found	 that	 the	
levels	 of	 p21WAF1	 in	 the	 nucleus	 change,	 in	 a	
manner	similar	to	ROCK,	in	response	to	changes	in	
the	 level	 of	NO:	NO	donors	 caused	 accumulation	
of	 p21WAF1	 in	 the	 nucleus	 (thus	 permitting	 it	 to	
induce	 cell	 cycle	 arrest),	 whereas	 NOS	 inhibitors	
resulted	 in	 a	 decrease	 in	 the	 levels	 of	 p21WAF1	
and	its	depletion	from	the	nucleus	(thus	segregating	
p21WAF1	 from	 the	 cdk’s	 and	preventing	 cell	 cycle	
arrest)	 (Fig.	 7Bd–f ).	 Importantly,	 treatment	 of	 the	
animal	caps	with	Y27632	together	with	NOS	inhibi-
tors	 reversed	 the	 effect	 of	 the	NOS	 inhibitors	 and	
restored	 the	 presence	 of	 p21WAF1	 in	 the	 nucleus	
thus	 reversing	 the	 effect	 of	 the	 NOS	 inhibitors	
(Fig.	7Bg	and	h).	This	suggests	that	in	the	ectoderm	
NO	 controls	 cell	 proliferation	 by	 regulating	 the	
distribution	of	p21WAF1	between	 the	nucleus	 and	
the	cytoplasm	via	the	RhoA-ROCK	pathway.
To	 further	 confirm	 that	 the	 distribution	 of	
p21WAF1	is	regulated	by	NO	and	to	investigate	the	
signals	involved,	we	injected	fertilized	eggs	with	trace	
amounts	 of	 mRNA	 coding	 for	 p21WAF1	 tagged	
with	 the	 c-myc	 epitope	 and	 followed	 the	 localiza-
tion	of	p21WAF1-myc	 in	 animal	 caps	 treated	with	
SNAP,	 L-NAME,	ODQ,	 or	 8-Br-cGMP.	We	 found	 that	 recombi-
nant	p21WAF1-myc	responded	to	the	NO	donor	and	inhibitor	in	a	
manner	similar	to	the	endogenous	p21WAF1	protein:	it	accumulated	
in	the	nucleus	in	response	to	SNAP	but	was	mostly	absent	from	the	
nucleus	 in	 response	 to	 L-NAME	 (Fig.	 7Ca–c).	Moreover,	 its	 pres-
Figure 8. (A) Dsh interacts with XNOS1. Cultured HEK293 cells were transfected with recom-
binant constructs coding for XNO-HA and Dsh-myc protein fusions separately or together. 
Protein complexes were immunoprecipitated from the cell lysates using antibodies to the HA 
and myc epitopes and the same antibodies were then used to probe the presence of Dsh and 
XNOS1 in the complexes using Western blots; antibodies used for immunoprecipitation and 
for Westerns are indicated. Input refers to the starting material. Due to large differences in the 
signal strength, for some of the lanes images of different exposures are combined. Amount 
of Dsh-myc protein in two top left lanes is very high and the band signals are oversaturated. 
(B) XNOS1 regulates the distribution of Dsh and the organization of the actin cytoskeleton. 2 
dorsal blastomeres of the 4-cell embryo were injected with XNOS1, dnXNOS1, or b-galacto-
sidase mRNA and neural tube was dissected from the epidermis at stage 28, stained in whole 
mount with anti-Dsh antibody (red) and falloidin (for polymerized actin) (green), flattened on 
the slide and the images oriented on the figures by lateral side down and medial side up. 
Note the loss of the spindle-like shape, the increased levels and loss of polarized distribution 
of Dsh, and the loss of the preferential localization of the actin filaments in cells of the embryos 
injected with dnXNOS1 mRNA but not with XNOS1 mRNA. Bar is 20 mm. (C) Schematic 
representation of two signaling pathways mediating the action of XNOS1 on cell division and 
cell movement during early Xenopus development.
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ence	in	the	nucleus	was	decreased	in	most	of	the	cells	of	animal	caps	
treated	 with	 ODQ	 and,	 conversely,	 was	 increased	 in	 the	 nucleus	
in	 cells	 treated	with	8-Br-cGMP	 (Fig.	 7Cd	 and	 e).	 Importantly,	 it	
was	still	 in	the	nucleus	when	cells	were	treated	with	a	combination	
of	 8-Br-cGMP	 and	 L-NAME	 (Fig.	 7Cf).	Together,	 these	 observa-
tions	confirm	that	NO	regulates	the	accumulation	of	p21WAF1	in	
the	 nucleus;	 suggest	 that	 the	NO-induced	 effects	 are	 independent	
of	 p21WAF1	 transcriptional	 activity	 (note	 that	 the	 myc-tagged	
p21WAF1	 protein	 encoded	 by	 the	 injected	 mRNA	 parallels	 the	
behavior	of	the	endogenous	p21WAF1);	indicate	that	this	distribu-
tion	 is	 mediated	 by	 the	 sGC-cGMP	 signaling;	 and	 suggest	 that,	
in	 its	 effects	 on	p21WAF1,	 cGMP	 signaling	 is	 downstream	of	 the	
NO-production	 step	 (since	 the	 effect	 of	 8-Br-cGMP	 trumps	 the	
effect	of	NOS	inhibitor	L-NAME).
PCP pathway mediates the action of NO on cell move‑
ment.	 Taken	 together,	 our	 results	 suggest	 that	 the	 action	 of	 NO	
on	 cell	 division	 in	 the	 developing	 embryo	 depends	 on	 the	 cGMP	
signaling	pathway.	In	contrast,	 the	effect	of	NO	on	cell	movement	
is	not	dependent	on	cGMP,	suggesting	that	it	 is	mediated	by	other	
signaling	 pathways.	 We	 therefore	 examined	 possible	 interactions	
between	NO	and	the	Wnt-Frizzled-Dsh	pathway,	a	major	pathway	
in	 the	developing	Xenopus	embryo	 that	 controls	PCP	required	 for	
directional	 cell	 movements.	 Dsh	 is	 a	 critical	 component	 of	 this	
pathway,	 serving	 as	 a	 scaffold	 and	 organizing	 protein	 complexes	
which	 regulate	 cytoskeletal	 remodeling,	 cell	 polarization,	 and	 cell	
movement.	Accumulation	of	Dsh	at	 the	cell	membrane	 is	 essential	
for	convergent	extension	(removal	of	Dsh	from	the	cell	membranes	
disrupts	convergent	extension;43	furthermore,	the	overall	level	of	Dsh	
is	also	critical	since	suppression	of	Dsh	degradation	can	also	disrupt	
convergent	extension44).
We	first	examined	interactions	between	XNOS1	and	Dsh	and	the	
effects	 of	NO	 on	 the	 cellular	 distribution	 of	Dsh.	When	 cultured	
cells	 were	 transfected	 with	 HA-tagged	 XNOS1	 and	 myc-tagged	
Dsh,	and	protein	interactions	were	probed	by	immunoprecipitation	
and	Western	blot	analysis,	we	 found	that	XNOS1-HA	was	present	
in	protein	 complexes	 immunoprecipitated	with	 an	 antibody	 to	 the	
myc	epitope	 (and	 thus	 to	Dsh-myc)	and,	conversely,	Dsh-myc	was	
present	 among	 proteins	 immunoprecipitated	 with	 an	 antibody	 to	
HA	epitope	(and	thus,	to	XNOS1-HA)	(Fig.	8A).	This	demonstrates	
that	XNOS1	is	present	in	protein	complexes	with	Dsh	and	suggests	
that	these	proteins	may	interact	in	vivo	(XNOS1	and	Dsh	have	PDZ	
domains	that	may	render	them	capable	of	such	interaction).
We	next	examined	the	distribution	of	endogenous	Dsh	in	embryos	
injected	 with	 either	 XNOS1	 or	 dnXNOS1;	 we	 also	 analyzed	 the	
status	 of	 the	 actin	 cytoskeleton.	We	 found	 that	 in	 the	 cells	 of	 the	
posterior	part	of	 the	neural	 tube	undergoing	convergent	extension,	
Dsh	 was	 localized	 near	 the	membranes	 and	 accumulated	 near	 the	
tips	of	the	spindle-shape	cells	(Fig.	8Ba).	In	these	cells	actin	filaments	
were	confined	to	the	cell	periphery.	Overexpression	of	XNOS1	did	
not	distort	the	spindle-like	shape	of	the	cells,	the	organization	of	the	
actin	cytoskeleton,	or	the	polarized	distribution	of	Dsh	(Fig.	8Bb).	In	
contrast,	in	embryos	injected	with	dnXNOS1	mRNA,	cells	lost	their	
spindle-like	shape,	the	actin	filaments	lost	their	preferential	periph-
eral	localization	and	instead	formed	extensive	network	across	the	cell,	
whereas	Dsh	became	more	abundant,	 lost	 its	polarized	distribution	
and	was	present	throughout	the	cell	(Fig.	8Bc).
Together	 these	 experiments	 suggest	 an	 interaction	 between	
XNOS1	 and	 Dsh,	 regulation	 of	 Dsh	 distribution	 and	 levels	 by	
XNOS1,	and	the	role	of	XNOS1	in	controlling	cell	shape	and	planar	
polarity.	Deficit	of	NO	distorts	the	planar	polarity	of	the	Dsh	distri-
bution	in	cells	engaged	in	convergent	extension	and	elevates	its	levels,	
disrupts	the	spindle-like	cell	shape	that	is	essential	for	their	directed	
movement	during	convergent	extension,	and	alters	the	organization	
of	the	actin	cytoskeleton	by	creating	extensive	intracellular	filament	
networks;	 these	 changes	may	 underlie	 the	 observed	 defects	 in	 cell	
movement	during	convergent	extension.
diScuSSioN
We	 have	 identified	 NO	 as	 a	 signal	 that	 coordinates	 morpho-
genetic	movements	 with	 the	 cell	 cycle	 during	 the	 development	 of	
Xenopus	 embryo.	NO	 both	 suppresses	 cell	 division	 and	 facilitates	
cell	movement.	This	dual	action	of	NO	is	crucial	in	the	developing	
neural	tissue	where	cells	divide	while	undergoing	convergent	exten-
sion;	in	the	axial	mesoderm,	where	cell	division	largely	ceases	before	
the	process	of	convergent	extension,	NO	acts	to	facilitate	cell	move-
ment	without	affecting	cell	proliferation.
Our	results	suggest	a	model	where	XNOS1	acts	through	two	sepa-
rate	 signaling	pathways	 to	 control	 cell	 division	 and	 cell	movement	
(Fig.	 8C).	 XNOS1	 regulates	 cell	 division	 via	 a	 cGMP-dependent	
pathway:	 XNOS1-produced	 NO	 activates	 sGC	 which,	 through	
production	 of	 cGMP,	 activates	 PKG.	 PKG	 is	 known	 to	 negatively	
regulate	RhoA39	 and	we	 consider	 that	 it	 is	 acting	 similarly	 in	 this	
pathway;	 thus,	 production	 of	 NO	 inhibits	 RhoA	 activity	 and	 the	
signaling	from	RhoA	to	ROCK.	This	leads	to	the	observed	nuclear	
accumulation	 of	 ROCK	 and	 p21WAF1,	 permitting	 inhibitory	
interactions	of	p21WAF1	with	cdks	and	subsequent	cell	cycle	arrest.	
Inhibition	 of	 XNOS1	 activity	 diminishes	 production	 of	 cGMP,	
increases	RhoA	and	ROCK	activity,	and	prevents	nuclear	accumula-
tion	 of	 p21WAF1,	 thus	 segregating	 it	 from	 its	 nuclear	 targets	 and	
interfering	with	its	ability	to	halt	the	cell	cycle,	eventually	leading	to	
an	increase	in	cell	number;	inhibition	of	ROCK	restores	the	nuclear	
accumulation	of	p21WAF1	and	rescues	the	NOS	inhibitors-induced	
changes	 in	 cell	 proliferation.	 Inhibition	 of	 NOS	 only	 affects	 cell	
division	in	the	neuroectoderm;	thus,	this	pathway	defines	the	antip-
roliferative	action	of	NO	in	neural	tissue.
In	this	model,	XNOS1	regulates	cell	movement	via	a	cGMP-inde-
pendent	pathway,	where	it	interacts	with	Dsh,	a	central	component	
of	the	PCP	pathway.	XNOS1	complexes	with	Dsh	(perhaps	through	
the	PDZ	domains	of	each	protein)	and	controls	planar	polarity	and	
turnover	of	Dsh.	Dsh	acts	as	a	positive	regulator	of	RhoA	and	they	
are	 found	 together	 in	 a	 complex;	 thus,	Dsh	may	 serve	 to	mediate	
the	 interaction	 between	 XNOS1	 and	 RhoA	 (perhaps	 involving	
Daam133)	 and	 allow	 S-nitrosylation	 of	 RhoA	 by	 NO,	 leading	 to	
further	suppression	of	RhoA	activity.38	Hence,	apart	from	activating	
cGMP	 signaling,	 XNOS1	 may	 exert	 its	 negative	 effect	 on	 RhoA	
through	 two	 additional	 mechanisms:	 through	 the	 control	 of	 the	
distribution	 and	overall	 levels	 of	Dsh	 and	 through	nitrosylation	of	
RhoA.	RhoA	regulates	ROCK	and,	eventually,	the	remodeling	of	the	
actin	cytoskeleton	necessary	for	convergent	extension.	Inhibition	of	
XNOS1	 compromises	 appropriate	 cellular	 distribution	 and	 degra-
dation	 of	 Dsh,	 increases	 RhoA	 activity,	 augments	 RhoA-ROCK	
signaling,	 hinders	 actin	 remodeling	 by	 ROCK,	 establishes	 a	 dense	
actin	network	throughout	the	cell,	changes	the	cell	shape,	and	leads	
to	defects	in	convergent	extension;	inhibition	of	ROCK	counteracts	
the	action	of	NOS	inhibitors	and	rescues	the	defects	in	convergent	
extension.	 Inhibition	 of	 NOS	 affects	 cell	 movement	 both	 in	 the	
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neuroectoderm	and	in	the	axial	mesoderm;	thus,	this	pathway	defines	
the	 action	 of	NO	during	 both	neural	 and	mesodermal	 convergent	
extension.
Thus,	our	model	 implies	 that	during	development,	cell	division	
and	cell	motility,	two	critical	processes	which	underlie	tissue	growth	
and	morphogenetic	movements	(such	as	convergent	extension),	rely	
on	 the	 same	 signaling	molecule,	NO.	Thus	 changes	 in	NO	 avail-
ability	affect	both	cell	division	and	cell	movements	in	a	reciprocally	
coordinated	manner:	an	 increase	 in	NO	production	 suppresses	cell	
proliferation	and	facilitates	cell	movement;	conversely,	a	decrease	in	
NO	production	 increases	 cell	 proliferation	 and	 impairs	 cell	move-
ment.	Since	NO	is	a	diffusible	messenger	and	can	function	in	both	
autocrine	 and	 paracrine	 modes,	 it	 may	 coordinate	 division	 and	
motility	between	adjacent	cells	and	thus,	both	within	and	between	
different	cell	layers	and	tissues.
This	 model	 reflects	 our	 conclusion	 that	 cell	 division	 and	 cell	
movement	are	controlled	through	different	mechanisms	and	can	be	
experimentally	 uncoupled.	This	 conclusion	 is	 supported	 by	 several	
observations:	 proliferation	 can	 be	 increased	 by	 ODQ	 without	
apparent	 defects	 in	 morphogenetic	 movements	 (Fig.	 5Ac,h,m	 and	
Bc,h);	 excessive	 proliferation,	 but	 not	 distorted	 cell	 movement,	
induced	 by	 NOS	 inhibitors	 can	 be	 rescued	 by	 8-Br-cGMP	 (Fig.	
5Ae,j,o	 and	 Be,j);	 when	 proliferation	 is	 suppressed	 by	 aphidicolin	
and	 hydroxyurea,	 convergent	 extension	 defects	 induced	 by	 NOS	
inhibitors	 are	 still	 apparent	 (Fig.	 4j);	 inhibition	 of	 NOS	 induces	
defects	 in	 convergent	 extension	 of	 non-dividing	 cells	 in	 the	 noto-
chord	(Fig.	3g–j).	Thus,	suppression	or	augmentation	of	cell	division	
through	the	cGMP	pathway	does	not	have	a	direct	effect	on	morpho-
genetic	 movements;	 conversely,	 defects	 in	 convergent	 extension,	
induced	by	the	inhibition	of	NOS,	cannot	be	rescued	by	suppressing	
cell	division.
Interestingly,	our	observations	suggest	that	cell	proliferation	and	
cell	movement	may	be	controlled	by	different	levels	of	NO:	changes	
in	cell	proliferation	(BrdU	incorporation	and	the	size	of	the	neural	
tube)	were	 evident	 at	 lower	 concentration	of	NOS	 inhibitors	 than	
changes	 in	 cell	movement	 (dorsal	 flexure	 and	 stunted	 body).	This	
suggests	that	low	levels	of	NO	may	induce	cell	motility,	whereas	cell	
cycle	 arrest	 may	 require	 higher	 concentrations	 of	 NO.	These	 two	
different	thresholds	for	the	effects	of	NO	provide	additional	support	
for	our	two	pathways	model.
Our	 results	 highlight	 RhoA	 as	 a	 crucial	 target	 of	 NO	 during	
development.	NO	acts	as	a	negative	regulator	of	RhoA	activity	and	
this	 may	 be	 achieved	 through	 at	 least	 three	 distinct	 mechanisms:	
activation	of	the	sGC	and	cGMP	signaling,	control	of	accumulation	
and	cellular	distribution	of	Dsh,	and	S-nitrosylation	of	RhoA.	The	
cGMP	 branch	may	 act	 through	 activation	 of	 PKG	 and	 inhibitory	
phosphorylation	of	RhoA	signaling	(e.g.,	by	augmenting	the	binding	
of	 RhoA	 to	 guanine	 dissociation	 factor	 (GDI).39	The	 importance	
of	 controlling	Dsh	 is	 related	 to	 the	 fact	 that	 the	planar	polarity	of	
Dsh	 distribution	 is	 necessary	 for	 convergent	 extension2	 and	 that	
Dsh	 localization	 to	 the	 cell	 membrane	 is	 crucial	 to	 its	 ability	 to	
activate	RhoA	during	convergent	extension;43	 furthermore,	 control	
of	 the	 intracellular	 levels	 of	 Dsh	 is	 critical	 for	 its	 proper	 action	
during	 convergent	 extension.44	 Finally,	 our	 finding	 that	 RhoA	 is	
S-nitrosylated	by	NO	in	vivo	and	that	inhibition	of	NOS	increases	
its	 activity	 raises	 a	 possibility	 that	 nitrosylation	 of	 critical	 cysteine	
residue(s)	 in	 RhoA	 may	 inhibit	 its	 activity,	 either	 directly,	 or	 by	
affecting	its	interactions	with	regulatory	proteins	(e.g.,	GEFs,	GAPs	
or	GDIs);	 indeed,	a	recent	report	demonstrates	that	S-nitrosylation	
of	RhoA	inhibits	its	activity.38
Our	 finding	 that	 the	 ROCK	 inhibitor	 Y27632	 rescues	 both	
excessive	 cell	proliferation	and	 impaired	axis	 extension	caused	by	a	
deficit	 of	NO	 supports	 the	notion	 that	 signaling	 from	XNOS1	 to	
RhoA-ROCK	is	crucial	for	both	cell	division	and	morphogenetic	cell	
movements.	However,	the	results	with	cGMP	pathway	agonists	and	
antagonists	 indicate	 that	 the	 proliferation-	 and	 movement-related	
control	 of	 the	 RhoA-ROCK	module	 by	 NO	 is	 achieved	 through	
different	 mechanisms	 and	 can	 be	 uncoupled.	 Furthermore,	 our	
conclusion	 that	 RhoA	 is	 involved	 in	 both	 pathways	 that	 mediate	
NO	action	during	early	Xenopus	development	is	consistent	with	the	
reported	effects	of	loss-	and	gain-of-function	mutations	of	RhoA	in	
the	Xenopus	 embryo:	 several	of	 the	 changes	 (reduced	eyes,	 smaller	
neural	 tubes,	 and	 microcephalic	 phenotypes)	 seen	 when	 RhoA	
activity	 is	 inhibited32	 are	 phenocopied	 by	 the	 changes	 induced	 by	
overexpression	 of	 XNOS1,	 a	 negative	 regulator	 of	 RhoA,	 whereas	
inhibition	 of	 directional	 cell	 movement	 and	 convergent	 extension	
induced	 by	 the	 constitutively	 active	 form	 of	 RhoA32-34	 is	 pheno-
copied	by	inhibition	of	XNOS1.
NO	and	RhoA	pathways	interact	in	several	physiological	settings,	
with	NO	acting	as	a	negative	regulator	of	RhoA-mediated	signaling	
(smooth	 muscle	 cell	 motility,17	 vasodilation	 in	 the	 aorta,35	 insu-
lin-induced	vasorelaxation,37	and	erectile	response36).	We	now	show	
that	cross-talk	between	the	NO	and	RhoA	pathways	 is	more	wide-
spread	and	is	critical	for	early	Xenopus	development.	More	generally,	
the	molecular	mechanism	we	outline	may	be	extensively	employed	in	
various	contexts	to	transduce	NO	signals	during	cell	differentiation	
and	organism	development.
We	have	discovered	that	NO	regulates	and	coordinates	cell	divi-
sion	and	cell	movement	in	early	vertebrate	development.	Deficits	in	
NO	availability,	by	uncoupling	 these	 tightly	coordinated	processes,	
may	underlie	developmental	abnormalities,	for	instance,	neural	tube	
defects	in	human	development.	It	is	possible	that	the	system	of	recip-
rocal	NO	control	of	cell	proliferation	and	cell	movement	has	been	
evolved	 because	 under	 certain	 circumstances	 division	 and	motility	
may	be	fundamentally	temporally	incompatible	and	NO	is	employed	
to	 permit	 one	 process	 to	 occur	 while	 simultaneously	 holding	 the	
other	in	check.
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